← boardnext 2026-08-12
ACRV
Acrivon Therapeuticsdistress 3/10 · well-funded / low risk$1.67-1%today-44% from 52w high
Oncology 1
Lead: serous endometrial cancer
Revenue
pre-revenue
Liquidity
$103M
Runway
1.6 yrs
Shares 1y
+36%
Price & events
-17.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-4.5%
1W
+2.5%
1M
-11.6%
3M
-18.5%
6M
+15.2%
1Y
-78.0%
2Y
—
5Y
-90.0%
All
Overview
- Market Cap
- $71.51M
- Volume
- 29.96K
- 52 Week Range
- $1.23 – $3.01
- Total Shares
- 42.80M
- Float Shares
- 27.93M
- Short %
- 9.91%
- % Held by Insiders
- 15.55%
- % Held by Institutions
- 47.38%
- RVOL
- 0.07x
- Beta
- 1.83
Pipeline stages · 1 programs
ACR-368, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-12 Estimated 50% readout ~2026-09-11 | Phase 1 | ACR-2316fast trackbreakthrough | Specific Advanced Solid Tumors | 100 | recruiting |
| 2027-05-30 Estimated 50% readout ~2027-07-14 | Phase 2 | ACR-368, Gemcitabinefast trackbreakthrough | Endometrial Adenocarcinoma | — | recruiting |
Catalyst news & presentations · 11
- fourth quarter of 2026Guided 70%enrollment completesecondaryPhase 2ACR-368 · Complete enrollment in Arm 3SEC 8-K
- Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)ACR-6840 · IND submissionSEC 8-K
- Mid-2026readoutPhase 1/2ACR-2316 · Initial clinical dataSEC 8-K
- 1H 2026trial initiationsecondaryPhase 2ACR-368 · Dose expansion startSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 2ACR-368 · Initial EU patient enrollment for Arm 3SEC 8-K
- during the European Society of Gynecological Oncology (ESGO) Congressconferencedata presentationsecondaryPhase 2ACR-368 · KOL panel discussion and overview of interim clinical data from the registrational-intent Phase 2b trial.SEC 8-K
- second half of 2025readoutPhase 1ACR-2316 · Initial clinical data from Phase 1 monotherapy trialSEC 8-K
- 2025-03-27trial discontinuedACR-368 · Ovarian cancer program deprioritizedSEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 1ACR-2316 · First-in-human dosing expected in Q4 2024SEC 8-K
- 2024-09-14fda agreementACR-2316 · IND cleared by FDA for ACR-2316SEC 8-K
- September 14, 2024conferencedata presentationsecondaryPhase 2ACR-368 · Presented Phase 2 data at ESMO 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $12 (+588% upside) · 6 analysts
- 2026-01-09Piper SandlerOverweight
- 2025-11-25HC Wainwright & Co.Buy
- 2025-08-14OppenheimerOutperform
- 2025-05-16Jones TradingBuy → Hold
- 2025-05-15OppenheimerOutperform
- 2025-03-28HC Wainwright & Co.Buy
Competitors — serous endometrial cancer
- none identified
Recent news
- 2026-07-22Acrivon Therapeutics (ACRV) Holds Steady Near Support Amid Low-Volume Trading - Institutional Flow Picks - dars.gov.et
- 2026-07-21Acrivon to Present Tumor Shrinkage and Partial Responses at AACR - Stock Titan
- 2026-07-21Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference - Yahoo! Finance Canada
- 2026-07-21Acrivon to Highlight the Power of its AP3 Platform for - GlobeNewswire
- 2026-07-18ACRV Stock Price, Quote & Chart - ChartMill
- 2026-07-15Trading Systems Reacting to (ACRV) Volatility - Stock Traders Daily
- 2026-07-13Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV) - Seeking Alpha
- 2026-06-27Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.